Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment
Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru
Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru https://ift.tt/2ZWKgCM July 12, 2020 at 06:20PM
Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru https://ift.tt/2ZWKgCM July 12, 2020 at 06:20PM
Comments
Post a Comment